Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / CRTX - Cortexyme: A Challenging Path Forward

CRTX - Cortexyme: A Challenging Path Forward

Cortexyme Inc.
  • The GAIN trial failed to meet its primary endpoints in the broader population of patients with mild to moderate Alzheimer’s disease.
  • Cortexyme presented data suggesting a pre-specified subset of patients with Pg DNA in their saliva can benefit from treatment with atuzaginstat.
  • Liver enzyme elevations pose a problem.
  • CRTX faces many obstacles but potentially has a treatment for AD that can benefit approximately 50% of AD patients.
  • AD is a $30-$50 B market.

For further details see:

Cortexyme: A Challenging Path Forward
Stock Information
Company Name: Cortexyme Inc.
Stock Symbol: CRTX
Market: NYSE
Website: cortexyme.com
Menu
CRTX CRTX Quote CRTX Short CRTX News CRTX Articles CRTX Message Board
Get CRTX Alerts

News, Short Squeeze, Breakout and More Instantly...